Corvus Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Corvus Pharmaceuticals, Inc. (CRVS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CRVS insiders buying or selling?
In the last 12 months, Corvus Pharmaceuticals, Inc. insiders reported 2 open-market purchases ($333.7K) and 0 sales ($0) — net buying of $333.7K. Since March 2018, Trabud has recorded 47 Form 4 filings for CRVS: 40 buys ($48.4M) and 7 sells ($62.6M).
Source: SEC EDGAR Form 4
Key Statistics (March 2018 – Jun 15, 2026)
Total Form 4 filings
47
SEC EDGAR
Insider filers
11
Insider buys (40)
$48.4M
Insider sells (7)
$62.6M
Insider sentiment
Net sellingNet insider flow of $14.2M in net selling since March 2018, and $333.7K in net buying over the last 12 months.
Recent CRVS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | David Scott Moore | Director | Purchase | 21.7K | $11.53 | $250.2K | SEC ↗ |
| May 20, 2026 | Richard A Miller MD | President and CEO | Purchase | 6.9K | $12.04 | $83.5K | SEC ↗ |
| Jul 2, 2025 | ORBIMED ADVISORS LLC | Director, 10% Owner | Sale | 1.2M | $4.16 | $4.9M | SEC ↗ |
| Jul 2, 2025 | Peter A. Thompson | Director, 10% Owner | Sale | 1.2M | $4.16 | $4.9M | SEC ↗ |
| May 7, 2024 | William Benton Jones | SVP, Pharmaceutical Development | Purchase | 20.0K | $1.73 | $34.6K | SEC ↗ |
| May 7, 2024 | Richard A Miller MD | President and CEO | Purchase | 577.6K | $1.73 | $1000.0K | SEC ↗ |
| May 16, 2023 | Linda Grais | Director | Purchase | 10.0K | $2.45 | $24.5K | SEC ↗ |
| Dec 20, 2022 | William Benton Jones | SVP, Pharmaceutical Development | Purchase | 20.0K | $0.79 | $15.8K | SEC ↗ |
| Dec 15, 2022 | Leiv Lea | Chief Financial Officer | Purchase | 34.0K | $0.75 | $25.6K | SEC ↗ |
| Dec 15, 2022 | Richard A Miller MD | President and CEO | Purchase | 60.0K | $0.75 | $44.8K | SEC ↗ |
| Sep 28, 2022 | Richard A Miller MD | President and CEO | Purchase | 25.0K | $0.76 | $19.1K | SEC ↗ |
| Sep 20, 2022 | Richard A Miller MD | President and CEO | Purchase | 20.0K | $0.81 | $16.3K | SEC ↗ |
| Jun 28, 2022 | Richard A Miller MD | President and CEO | Purchase | 10.0K | $1.01 | $10.1K | SEC ↗ |
| Jun 6, 2022 | Richard A Miller MD | President and CEO | Purchase | 5.9K | $0.98 | $5.8K | SEC ↗ |
| Apr 1, 2022 | Richard A Miller MD | President and CEO | Purchase | 15.0K | $1.64 | $24.5K | SEC ↗ |
| Mar 17, 2022 | Leiv Lea | Chief Financial Officer | Purchase | 49.0K | $1.57 | $77.0K | SEC ↗ |
| Mar 17, 2022 | Richard A Miller MD | President and CEO | Purchase | 30.0K | $1.49 | $44.6K | SEC ↗ |
| Oct 1, 2021 | EcoR1 Capital, LLC | 10% Owner | Sale | 5.0M | $5.01 | $25.1M | SEC ↗ |
| Sep 22, 2021 | ORBIMED ADVISORS LLC | Director, 10% Owner | Sale | 1.1M | $6.09 | $6.8M | SEC ↗ |
| Sep 22, 2021 | Peter A. Thompson | Director, 10% Owner | Sale | 1.1M | $6.09 | $6.8M | SEC ↗ |
| Aug 24, 2021 | Richard A Miller MD | President and CEO | Purchase | 10.0K | $1.93 | $19.3K | SEC ↗ |
| May 5, 2021 | Richard A Miller MD | President and CEO | Purchase | 35.7K | $2.80 | $100.0K | SEC ↗ |
| Feb 19, 2021 | ORBIMED ADVISORS LLC | Director, 10% Owner | Purchase | 1.3M | $3.50 | $4.5M | SEC ↗ |
| Feb 19, 2021 | Peter A. Thompson | Director, 10% Owner | Purchase | 1.3M | $3.50 | $4.5M | SEC ↗ |
| Feb 17, 2021 | Richard A Miller MD | President and CEO | Purchase | 100.0K | $3.50 | $350.0K | SEC ↗ |
Showing the 25 most recent of 47 Form 4 filings for Corvus Pharmaceuticals, Inc..
Most active CRVS insiders
- Richard A Miller MD21 filings
- ORBIMED ADVISORS LLC6 filings
- Peter A. Thompson6 filings
- Leiv Lea4 filings
- Novo Holdings A/S3 filings
Ask anything about CRVS insider activity
Use Trabud's AI agent to query Corvus Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me CRVS CEO purchases this year" or compare it against any other ticker.
Open the AI agentCRVS insider trading FAQ
Are Corvus Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, Corvus Pharmaceuticals, Inc. insiders reported 2 open-market purchases ($333.7K) and 0 sales ($0) — net buying of $333.7K. Since March 2018, Trabud has recorded 47 Form 4 filings for CRVS: 40 buys ($48.4M) and 7 sells ($62.6M). Over the full record that is net selling of $14.2M.
How many insiders trade CRVS stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Corvus Pharmaceuticals, Inc.. The most recent filing was accepted on Jun 15, 2026.
Where does Trabud get CRVS insider trading data?
All CRVS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.